- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02669888
Indigo Naturalis in Treating Atopic Dermatitis Topically
Efficacy and Safety of Topical Indigo Naturalis in Treating Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that most commonly occurs in children. The aims of this project are:
- To evaluate the efficacy of indigo naturalis ointment in treating AD topically;
- To evaluate the safety of indigo naturalis ointment in treating AD topically;
- To investigate whether indigo naturalis ointment treatment is associated with a change in total IgE, cytokines, eosinophils, and CRP in patients with AD;
- To evaluate whether indigo naturalis ointment treatment improves the quality of life in patients with AD.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Atopic dermatitis (AD) is a chronic inflammatory skin disorder that most commonly occurs in children. AD is characterized by itchy and dry skin that affects approximately 5 to 20% of children in the world. Currently, corticosteroids are the most widely prescribed medication in treating AD; however, there are concerns regarding the side effects such as skin atrophy, telangiectasia, striae, folliculitis and adrenocortical suppression that inhibits growth in children. Many patients and families seek complementary and alternative medications such as traditional Chinese medicine (TCM). In TCM, indigo naturalis has been used to treat various infectious and inflammatory skin diseases for hundreds of years. Ancient TCM literature has recorded that indigo naturalis is also effective in treating facial eczema (AD) in infants.
The aims of this project are: (1) To evaluate the efficacy of indigo naturalis ointment in treating AD topically; (2) To evaluate the safety of indigo naturalis ointment in treating AD topically; (3) To investigate whether indigo naturalis ointment treatment is associated with a change in total IgE, cytokines, eosinophils, and CRP in patients with AD; (4) To evaluate whether indigo naturalis ointment treatment improves the quality of life in patients with AD.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Kelung, Taiwan, 204
- Chang Gung Memorial Hospital at Keelung
-
Taipei, Taiwan, 105
- Chang Gung Memorial Hospital at Taipei
-
Taoyuan, Taiwan, 333
- Chang Gung Memorial Hospital at Linkou
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Between 6 and 65 years old, female or male.
- Atopic dermatitis fulfilling the diagnostic criteria of Williams et al.
- Atopic dermatitis involving <40% of BSA. (Base on the BSA result of Screening)
- An Investigator's Global Assessment (IGA) score of 2, 3 or 4 which corresponds to mild, moderate or severe disease. (Base on the IGA result of Screening)
- Female patients of child-bearing age with negative pregnancy test at screening.
- Female patients of child-bearing age that agree to continue using birth control measures approved by the investigator and agree not to lactate for the duration of the study.
- Agree to only receive stable doses of an additive-free, basic bland emollient for at least 7 days before baseline (day0)
- Willing to comply with study protocol and agree to sign an informed consent form.
Exclusion Criteria:
- Having a history of topical or systematical hypersensitivity to indigo naturalis or its excipient (e.g. beeswax) in ointment
- Undergoing phototherapy (e.g. UVB, PUVA) or systemic therapy (e.g. Immunosuppressive agents) within 30 days.
- Having used topical therapy (e.g. topical corticosteroids) for dermatitis within 7 days before the first application of the study medication.
- Having a significant concurrent disease, such as: significant abnormalities in hematology, severe uncontrolled metabolic syndrome (e.g., hypertension, diabetes mellitus, metabolic arthritis, hyperthyroidism), psychiatric disease, cancer or AIDS.
- Having abnormal liver or renal function (AST/ALT >3 x ULN, creatinine >2.0 mg/dl).
- Women who are lactating, pregnant or preparing to be pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Indigo naturalis ointment
|
Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
Other Names:
|
PLACEBO_COMPARATOR: Placebo
|
Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage change in Eczema Area Severity Index (EASI) scores from baseline to week 6
Time Frame: 6 weeks
|
The Eczema Area and Severity Index (EASI) is used to measure the disease severity of erythema, infiltration/papulation, excoriation, and lichenification each on a scale of 0 to 3 (none to severe) as well as the percentage of disease area on a scale of 0 to 6 for the head ⁄ neck, upper limb, trunk and lower limb body regions. Each body region score is calculated by multiplying the disease severity score by the disease area score and by the multiplier. The scores are summed to give the total EASI score, ranging from 0 to a maximum 72. The mean percentage change in EASI = (EASI baseline-EASI post-treat) / EASI baseline x 100% |
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects who have achieved EASI-50, EASI-75, and EASI-90 after 6 weeks of treatment
Time Frame: 6 weeks
|
It is defined as at least 50%, 75%, and 90% reduction in EASI score relative to the baseline.
|
6 weeks
|
Proportion of subjects with a change in Investigator's Global Assessment (IGA, range 0-5) from baseline to week 6.
Time Frame: 6 weeks
|
|
6 weeks
|
The mean percentage change in Total Body Surface Area involved with AD (BSA, range 0%-100%) from baseline to week 6.
Time Frame: 6 weeks
|
BSA is total Body Surface Area involved, ranging from 0% (none) to 100% (total body surface involved)
|
6 weeks
|
The mean change in pruritus score (10-cm visual analogue scale) from baseline to week 6.
Time Frame: 6 weeks
|
Visual Analogue Scale (VAS) for pruritus severity rates from 0 (no itching) to 10 (very severe itching)
|
6 weeks
|
Clinical-immunological correlation between the treatment outcome and the changes in the level of immunoglobin E (IgE), cytokines, eosinophil count, and C-reactive protein (CRP) in the peripheral blood from baseline to week 6.
Time Frame: 6 weeks
|
Measuring the correlations of treatment by EASI score and BSA, with the changes in IgE, eosinophils, cytokines (IL-1β, IL-6, TNF-α…) from baseline to week 6.
|
6 weeks
|
The mean change in Dermatology Life Quality Index (DLQI)from baseline to week 6
Time Frame: 6 weeks
|
The DLQI is a self-administered 10-item questionnaire, ranges from 0 (best) to 30 (worst); the higher the score, the more quality of life is impaired. For subjects from age 6 to age 16, children's DLQI (CDLQI) will used. |
6 weeks
|
Physician's Global Assessment (PGA ) at week 6.
Time Frame: 6 weeks
|
0 = Symptoms cleared or excellent improvement of 90-100%; 1 = Marked improvement of 75-89%; 2 = Moderate improvement of 50-74%; 3 = Slight improvement of 3049%; 4 = No appreciable improvement of 029%; 5 = Worsening of the condition
|
6 weeks
|
Subject's Global Assessment (SGA) at week 6.
Time Frame: 6 weeks
|
0 = Symptoms cleared or excellent improvement of 90-100%; 1 = Marked improvement of 75-89%; 2 = Moderate improvement of 50-74%; 3 = Slight improvement of 3049%; 4 = No appreciable improvement of 029%; 5 = Worsening of the condition
|
6 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MOST 104-2325-B-182A-005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Atopic Dermatitis
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
Regeneron PharmaceuticalsSanofiRecruitingModerate-to-Severe Atopic Dermatitis | Atopic EczemaUnited States
Clinical Trials on Indigo naturalis ointment
-
Yin-ku LinCompletedPsoriasis VulgarisTaiwan
-
Chang Gung Memorial HospitalNational Science Council, TaiwanCompleted
-
China Medical University HospitalCompleted
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangzhou First People's... and other collaboratorsRecruitingChildhood ALL | Arsenic TrioxideChina
-
Chang Gung Memorial HospitalMinistry of Science and Technology, TaiwanCompleted
-
Xinhua Hospital, Shanghai Jiao Tong University...Not yet recruiting
-
Chang Gung Memorial HospitalCompleted
-
Peking University People's HospitalMinistry of Science and Technology of the People´s Republic of ChinaNot yet recruitingAcute Promyelocytic Leukaemia
-
First Affiliated Hospital Xi'an Jiaotong UniversityRecruitingAcute Myeloid LeukemiaChina
-
Azienda Ospedaliera Universitaria SeneseUnknown